RARE Quote, Financials, Valuation and Earnings

iBio has a net margin of -95.72% compared to Ultragenyx Pharmaceutical's net margin of -4444.57%. Ultragenyx Pharmaceutical's return on equity of -226.56% beat iBio's return on equity of -148.3%.

Ultragenyx Pharmaceutical has a consensus price target of $92.95, signalling upside risk potential of 123.98%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 46.94%. Given that Ultragenyx Pharmaceutical has higher upside potential than iBio, analysts believe Ultragenyx Pharmaceutical is more attractive than iBio.

Ultragenyx Pharmaceutical has a beta of 0.576, which suggesting that the stock is 42.385% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.5M, which are larger than iBio quarterly revenues of $175K. Ultragenyx Pharmaceutical's net income of -$133.5M is lower than iBio's net income of -$4M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.90x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -95.72% compared to Ultragenyx Pharmaceutical's net margin of -49.65%. Ultragenyx Pharmaceutical's return on equity of -226.56% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ultragenyx Pharmaceutical has a consensus price target of $92.95, signalling upside risk potential of 123.98%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe NovaBay Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.576, which suggesting that the stock is 42.385% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ultragenyx Pharmaceutical's net income of -$133.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.90x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -95.72% compared to Ultragenyx Pharmaceutical's net margin of -2357.27%. Ultragenyx Pharmaceutical's return on equity of -226.56% beat Palatin Technologies's return on equity of --.

Ultragenyx Pharmaceutical has a consensus price target of $92.95, signalling upside risk potential of 123.98%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Palatin Technologies is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.576, which suggesting that the stock is 42.385% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Ultragenyx Pharmaceutical's net income of -$133.5M is lower than Palatin Technologies's net income of -$7.8M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.90x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -95.72% compared to Ultragenyx Pharmaceutical's net margin of --. Ultragenyx Pharmaceutical's return on equity of -226.56% beat Theriva Biologics's return on equity of --.

Ultragenyx Pharmaceutical has a consensus price target of $92.95, signalling upside risk potential of 123.98%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5591.82%. Given that Theriva Biologics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Theriva Biologics is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.576, which suggesting that the stock is 42.385% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.5M, which are larger than Theriva Biologics quarterly revenues of --. Ultragenyx Pharmaceutical's net income of -$133.5M is lower than Theriva Biologics's net income of -$7.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 6.90x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.